Chapter 7
Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes
Book Editor(s):Chuang Lu,
Albert P. Li,
Chuang Lu
Department of DMPK, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Search for more papers by this authorAlbert P. Li
In Vitro ADMET Laboratories, Columbia, Maryland, USA
Search for more papers by this authorFirst published: 14 December 2009
Summary
This chapter contains sections titled:
-
Introduction
-
Cytochrome P 450 Cycle, Unified Mechanism, and Inhibition Mechanisms
-
Cytochrome P 450 Assay Approaches
-
Predicting Drug–Drug Interactions from in Vitro Inhibition Data
-
Conclusions
-
References
REFERENCES
- Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002; 30(12): 1497–1503.
- Backes WL, Kelley RW. Organization of multiple cytochrome P 450s with NADPH-cytochrome P 450 reductase in membranes. Pharmacol Ther 2003; 98(2): 221–233.
- Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug—drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31(7): 815–832.
- Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Nat Acad Sci USA 1989; 86(20): 7696–7700.
- Cali JJ, Ma D, Sobol M, Simpson DJ, Frackman S, Good TD, Daily WJ, Liu D. Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol 2006; 2(4): 629–645.
- Chauret N, Tremblay N, Lackman RL, Gauthier JY, Silva JM, Marois J, Yergey JA, Nicoll-Griffith DA. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe. Anal Biochem 1999; 276(2): 215–226.
- Chauret N, Dobbs B, Lackman RL, Bateman K, Nicoll-Griffith DA, Stresser DM, Ackermann JM, Turner SD, Miller VP, Crespi CL. The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes. Drug Metab Dispos 2001; 29(9): 1196–1200.
- Cohen LH, Remley MJ, Raunig D, Vaz ADN. In vitro drug interactions of cytochrome P450: An evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003; 31(8): 1005–1015.
- Dixit V, Hariparsad N, Desai P, Unadkat JD. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm Drug Dispos 2007; 28(5): 257–262.
- Einolf HJ. Comparison of different approaches to predict metabolic drug—drug interactions. Xenobiotica 2007; 37(10/11): 1257–1294.
- Fairman DA, Collins C, Chapple S. Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? Drug Metab Dispos Biol Fate Chem 2007; 35(12): 2159–2165.
- Fasco MJ, Piper LJ, Kaminsky LS. Biochemical applications of a quantitative high-pressure liquid chromatographic assay of warfarin and its metabolites. J Chromatogr 1977; 131: 365–373.
- FDA 2006 http://www.fda.gov/cder/drug/drugInteractions/default.htm (accessed December 15, 2007).
- Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug—drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 2007; 8(7): 685–693.
- Gao H, Yao L, Mathieu HW, Zhang Y, Maurer TS, Troutman MD, Scott DO, Ruggeri RB, Lin J. In silico modeling of non-specific binding to human liver microsomes. Drug Metab Dispos 2008; 36(10): 2130–2135.
- Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro—in vivo extrapolation. Curr Drug Metab 2006; 7(3): 315–334.
- Ghosal A, Hapangama N, Yuan Y, Lu X, Horne D, Patrick JE, Zbaida S. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes. Biopharm Drug Dispos 2003; 24(9): 375–384.
- Guengerich FP. Cytochromes P450, drugs, and diseases. Mol Intervent 2003; 3(4): 194–204.
- Hallifax D, Houston JB. Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 2006; 34(4): 724–726.
- Hutzler JM, Powers FJ, Wynalda MA, Wienkers LC. Effect of carbonate anion on cytochrome P450 2D6-mediated metabolism in vitro: the potential role of multiple oxygenating species. Arch Biochem Biophys 2003; 417(2): 165–175.
- Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 2006; 36(6): 499–513.
- Ishii M, Xu BQ, Ding LR, Fischer NE, Inaba T. Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and γ-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat. Toxicol Lett 2001; 119(3): 219–225.
- Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005; 22(1): 103–112.
- Ito K, Hallifax D, Obach RS, Houston JB. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug–drug interactions: CYP2D6 paradigm. Drug Metab Dispos 2005; 33(6): 837–844.
- Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007; 8(5): 407–447.
- Kanamitsu S-I, Ito K, Sugiyama Y. Quantitative prediction of in vivo drug–drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 2000; 17(3): 336–343.
- Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999; 48(5): 716–727.
- Khan KK, He YQ, Domanski TL, Halpert JR. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 2002; 61(3): 495–506.
- Kim M-J, Kim H, Cha I-J, Park J-S, Shon J-H, Liu K-H, Shin J-G. High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19(18): 2651–2658.
- Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 1987; 162(1): 24–32.
- Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 2006; 34(12): 1966–1975.
-
Lee JS, Obach RS, Fisher MB. Drug Metabolizing Enzymes: Cytochrome P450 in Drug Discovery and Development. 2003. New York: Marcel Dekker.
10.1201/9781420028485 Google Scholar
- Madan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodrigues AD, editor. Drugs and the Pharmaceutical Sciences, Vol. 116, Drug–Drug Interactions. New York: Marcel Dekker, 2002, pp. 217–294.
- Maenpaa J, Hall SD, Ring BJ, Strom SC, Wrighton SA. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998; 8(2): 137–155.
-
Makris TM, Denisov I, Schlichting I, Sligar SG. Activation of molecular oxygen by cytchrome P450. In: Ortiz de Montellano PR, editor, Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed. New York: Kluwer Academic, 2005, pp. 149–182.
10.1007/0-387-27447-2_5 Google Scholar
- Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 2003; 31(5): 606–611.
- Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28(9): 1031–1037.
- Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL. Fluorometric high-throughput screening for inhibitors of cytochrome P450. Annals of the New York Academy of Sciences, Vol. 919, Toxicology for the Next Millennium. 2000, 26–32.
- Nath A, Atkins WM. Principal component analysis of CYP2C9 and CYP3A4 probe substrate/inhibitor panels. Drug Metab Dispos 2008; 36(11): 2151–2155.
- Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. In vitro cytochrome P450 inhibition data and the prediction of drug–drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78(6): 582–592.
- Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 2006; 316(1): 336–348.
- Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 2007; 35(2): 246–255.
- O'Donnell CJ, Grime K, Courtney P, Slee D, Riley RJ. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting. Drug Metab Dispos 2007; 35(3): 381–385.
-
Ortiz de Montellano PR, editor. Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed. New York: Kluwer Academic/Plenum Publishers, 2005.
10.1007/b139087 Google Scholar
- Powis G, Jansson I, Schenkman JB. The effects of albumin upon the spectral changes and metabolism by the hepatic microsomal fraction. Arch Biochem Biophys 1977; 179(1): 34–42.
- Purdon MP, Lehman-McKeeman LD. Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites. J Pharmacol Toxicol Methods 1997; 37(2): 67–73.
- Riley RJ, Grime K, Weaver R. Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 2007; 3(1): 51–66.
- Rowland A, Elliot DJ, Knights KM, Mackenzie PI, Miners JO. The “albumin effect” and in vitro–in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 2008; 36(5): 870–877.
- Rowland M, Matin SB. Kinetics of drug—drug interactions. J Pharmacokine Biopharm 1973; 1(6): 553–567.
- Smith D, Sadagopan N, Zientek M, Reddy A, Cohen L. Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J Chromatog B: Anal Technol Biomed Life Sci 2007; 850(1–2): 455–463.
- Sykes MJ, Sorich MJ, Miners JO. Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. J Chem Inf Model 2006; 46(6): 2661–2673.
- Tolonen A, Petsalo A, Turpeinen M, Uusitalo J, Pelkonen O. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 2007; 42(7): 960–966.
- Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—toward a consensus. Clin Pharmacol Ther 2001; 70(2): 103–114.
- Venkatakrishnan K, Obach RS. In vitro—in vivo extrapolation of CYP2D6 inactivation by paroxetine: Prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 2005; 33(6): 845–852.
- von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998; 87(10): 1184–1189.
- Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004; 32(6): 647–660.
- Wang Y-H, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004; 32(2): 259–266.
- Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000; 32(3&4): 339–361.
- Xu BQ, Ishii M, Ding LR, Fischer NE, Inaba T. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life Sci 2003; 72(17): 1953–1962.
- Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008; 9(5): 384–393.
- Zhang H, Davis CD, Sinz MW, Rodrigues AD. Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 2007: 3(5): 667–687.
